These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

818 related articles for article (PubMed ID: 21642685)

  • 1. KIT as a therapeutic target in metastatic melanoma.
    Carvajal RD; Antonescu CR; Wolchok JD; Chapman PB; Roman RA; Teitcher J; Panageas KS; Busam KJ; Chmielowski B; Lutzky J; Pavlick AC; Fusco A; Cane L; Takebe N; Vemula S; Bouvier N; Bastian BC; Schwartz GK
    JAMA; 2011 Jun; 305(22):2327-34. PubMed ID: 21642685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.
    Hodi FS; Corless CL; Giobbie-Hurder A; Fletcher JA; Zhu M; Marino-Enriquez A; Friedlander P; Gonzalez R; Weber JS; Gajewski TF; O'Day SJ; Kim KB; Lawrence D; Flaherty KT; Luke JJ; Collichio FA; Ernstoff MS; Heinrich MC; Beadling C; Zukotynski KA; Yap JT; Van den Abbeele AD; Demetri GD; Fisher DE
    J Clin Oncol; 2013 Sep; 31(26):3182-90. PubMed ID: 23775962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT.
    Handolias D; Hamilton AL; Salemi R; Tan A; Moodie K; Kerr L; Dobrovic A; McArthur GA
    Br J Cancer; 2010 Apr; 102(8):1219-23. PubMed ID: 20372153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel somatic KIT exon 8 mutation with dramatic response to imatinib in a patient with mucosal melanoma: a case report.
    Rapisuwon S; Parks K; Al-Refaie W; Atkins MB
    Melanoma Res; 2014 Oct; 24(5):509-11. PubMed ID: 25003536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607).
    Kalinsky K; Lee S; Rubin KM; Lawrence DP; Iafrarte AJ; Borger DR; Margolin KA; Leitao MM; Tarhini AA; Koon HB; Pecora AL; Jaslowski AJ; Cohen GI; Kuzel TM; Lao CD; Kirkwood JM
    Cancer; 2017 Jul; 123(14):2688-2697. PubMed ID: 28334439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. c-Kit inhibitors for unresectable or metastatic mucosal, acral or chronically sun-damaged melanoma: a systematic review and one-arm meta-analysis.
    Steeb T; Wessely A; Petzold A; Kohl C; Erdmann M; Berking C; Heppt MV
    Eur J Cancer; 2021 Nov; 157():348-357. PubMed ID: 34562816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response to imatinib mesylate depends on the presence of the V559A-mutated KIT oncogene.
    Terheyden P; Houben R; Pajouh P; Thorns C; Zillikens D; Becker JC
    J Invest Dermatol; 2010 Jan; 130(1):314-6. PubMed ID: 19812602
    [No Abstract]   [Full Text] [Related]  

  • 8. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification.
    Guo J; Si L; Kong Y; Flaherty KT; Xu X; Zhu Y; Corless CL; Li L; Li H; Sheng X; Cui C; Chi Z; Li S; Han M; Mao L; Lin X; Du N; Zhang X; Li J; Wang B; Qin S
    J Clin Oncol; 2011 Jul; 29(21):2904-9. PubMed ID: 21690468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition.
    Carvajal RD; Lawrence DP; Weber JS; Gajewski TF; Gonzalez R; Lutzky J; O'Day SJ; Hamid O; Wolchok JD; Chapman PB; Sullivan RJ; Teitcher JB; Ramaiya N; Giobbie-Hurder A; Antonescu CR; Heinrich MC; Bastian BC; Corless CL; Fletcher JA; Hodi FS
    Clin Cancer Res; 2015 May; 21(10):2289-96. PubMed ID: 25695690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of clinical efficacy of imatinib in metastatic melanoma.
    Ugurel S; Hildenbrand R; Zimpfer A; La Rosée P; Paschka P; Sucker A; Keikavoussi P; Becker JC; Rittgen W; Hochhaus A; Schadendorf D
    Br J Cancer; 2005 Apr; 92(8):1398-405. PubMed ID: 15846297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new KIT mutation (N505I) in acral melanoma confers constitutive signaling, favors tumorigenic properties, and is sensitive to imatinib.
    Allegra M; Giacchero D; Segalen C; Dumaz N; Butori C; Hofman V; Hofman P; Lacour JP; Bertolotto C; Bahadoran P; Ballotti R
    J Invest Dermatol; 2014 May; 134(5):1473-1476. PubMed ID: 24317392
    [No Abstract]   [Full Text] [Related]  

  • 12. Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma.
    Zukotynski K; Yap JT; Giobbie-Hurder A; Weber J; Gonzalez R; Gajewski TF; O'Day S; Kim K; Hodi FS; Van den Abbeele AD
    Cancer Imaging; 2014 Nov; 14(1):30. PubMed ID: 25609545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of resistance to imatinib mesylate in KIT-positive metastatic uveal melanoma.
    Calipel A; Landreville S; De La Fouchardière A; Mascarelli F; Rivoire M; Penel N; Mouriaux F
    Clin Exp Metastasis; 2014 Jun; 31(5):553-64. PubMed ID: 24652072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates.
    Woodman SE; Trent JC; Stemke-Hale K; Lazar AJ; Pricl S; Pavan GM; Fermeglia M; Gopal YN; Yang D; Podoloff DA; Ivan D; Kim KB; Papadopoulos N; Hwu P; Mills GB; Davies MA
    Mol Cancer Ther; 2009 Aug; 8(8):2079-85. PubMed ID: 19671763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imatinib targeting of KIT-mutant oncoprotein in melanoma.
    Jiang X; Zhou J; Yuen NK; Corless CL; Heinrich MC; Fletcher JA; Demetri GD; Widlund HR; Fisher DE; Hodi FS
    Clin Cancer Res; 2008 Dec; 14(23):7726-32. PubMed ID: 19047099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A potential role for nilotinib in KIT-mutated melanoma.
    Tran A; Tawbi HA
    Expert Opin Investig Drugs; 2012 Jun; 21(6):861-9. PubMed ID: 22500535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of imatinib mesylate in patients with metastatic melanoma.
    Kim KB; Eton O; Davis DW; Frazier ML; McConkey DJ; Diwan AH; Papadopoulos NE; Bedikian AY; Camacho LH; Ross MI; Cormier JN; Gershenwald JE; Lee JE; Mansfield PF; Billings LA; Ng CS; Charnsangavej C; Bar-Eli M; Johnson MM; Murgo AJ; Prieto VG
    Br J Cancer; 2008 Sep; 99(5):734-40. PubMed ID: 18728664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Major response to imatinib mesylate in KIT-mutated melanoma.
    Hodi FS; Friedlander P; Corless CL; Heinrich MC; Mac Rae S; Kruse A; Jagannathan J; Van den Abbeele AD; Velazquez EF; Demetri GD; Fisher DE
    J Clin Oncol; 2008 Apr; 26(12):2046-51. PubMed ID: 18421059
    [No Abstract]   [Full Text] [Related]  

  • 19. Anal mucosal melanoma with KIT-activating mutation and response to imatinib therapy--case report and review of the literature.
    Satzger I; Küttler U; Völker B; Schenck F; Kapp A; Gutzmer R
    Dermatology; 2010; 220(1):77-81. PubMed ID: 19996579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group.
    Debiec-Rychter M; Dumez H; Judson I; Wasag B; Verweij J; Brown M; Dimitrijevic S; Sciot R; Stul M; Vranck H; Scurr M; Hagemeijer A; van Glabbeke M; van Oosterom AT;
    Eur J Cancer; 2004 Mar; 40(5):689-95. PubMed ID: 15010069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.